Publication: Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial
6
0
Issued Date
2024-12-01
Resource Type
eISSN
14752891
Scopus ID
2-s2.0-85205527050
Pubmed ID
39354480
Journal Title
Nutrition Journal
Volume
23
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nutrition Journal Vol.23 No.1 (2024)
Suggested Citation
Yaikwawong M., Jansarikit L., Jirawatnotai S., Chuengsamarn S. Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial. Nutrition Journal Vol.23 No.1 (2024). doi:10.1186/s12937-024-01022-3 Retrieved from: https://hdl.handle.net/20.500.14740/20594
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression. Objective: To assess the efficacy of improving type 2 diabetes (T2DM). Study design: This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes. Methods: All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention. Results: After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001. Conclusions: A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial. Trial registration: Thai clinical trials regentrify no.20140303003.